Curious to see your top suppliers emissions?
Book a demo for a pilot project
Intellia Therapeutics, Inc.
Pharmaceutical Preparation ManufacturingUnited States
Last verified 8 months agointelliatx.com
Intellia Therapeutics, Inc., a pioneering biotechnology company based in the United States, is at the forefront of gene editing and therapeutic innovation. Founded in 2014, Intellia has rapidly established itself within the industry, focusing on developing transformative treatments for genetic diseases using its proprietary CRISPR/Cas9 technology.
With its headquarters in Cambridge, Massachusetts, Intellia operates in key regions across the US and globally, driving advancements in the field of genomic medicine. The company’s core offerings include its groundbreaking therapies aimed at addressing conditions such as transthyretin amyloidosis and other rare diseases, setting it apart through its commitment to precision and efficacy.
Intellia's notable achievements include successful clinical trials and strategic partnerships, solidifying its position as a leader in the gene editing landscape and contributing to the evolution of next-generation therapeutics.
23
DitchCarbon score
-17 vs industry average
Intellia Therapeutics, Inc.’s score of 23 is lower than 33% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Intellia Therapeutics, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for Intellia Therapeutics, Inc. yet.
Intellia Therapeutics, Inc.'s reported carbon emissions
Intellia Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures for Scope 1, Scope 2, and Scope 3 emissions. Consequently, there are no verified totals or reduction targets available at this time.
The company has not established any documented reduction initiatives or commitments to climate pledges, nor are there any targets set through the Science Based Targets initiative (SBTi). As such, Intellia Therapeutics appears to be in the early stages of developing its climate strategy and emissions reporting framework.
In the context of the biotechnology industry, it is increasingly important for companies to adopt transparent climate commitments and reduction strategies to align with global sustainability goals. As Intellia Therapeutics progresses, stakeholders will likely look for future disclosures regarding their carbon footprint and climate action plans.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Intellia Therapeutics, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Intellia Therapeutics, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisationsNo peer comparison is available for Intellia Therapeutics, Inc. yet.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more